Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Srx246. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 20/20 | 1.00 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Srx246 SCHEMBL2776810 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| Srx246 SCHEMBL3824717 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| SCHEMBL18648378 | 0.92 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| SCHEMBL2776372 | 0.92 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| SCHEMBL2779660 | 0.92 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| SCHEMBL14198966 | 0.92 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| SCHEMBL19521786 | 0.92 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| SCHEMBL21201759 | 0.89 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| SCHEMBL19521785 | 0.89 | AVPR1A (1.00) | AVPR1AAVPR1B | |
| SCHEMBL2779633 | 0.89 | AVPR1A (1.00) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195496-A1 | AVPR1A BLOCKADE TO REDUCE SOCIAL ISOLATION-INDUCED ANXIETY IN FEMALES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-06-19 | — | — | US | claimed |
| WO-2023164710-A1 | AVPR1A BLOCKADE TO REDUCE SOCIAL ISOLATION-INDUCED ANXIETY IN FEMALES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | WO | claimed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | claimed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | claimed |
| US-20250195496-A1 | AVPR1A BLOCKADE TO REDUCE SOCIAL ISOLATION-INDUCED ANXIETY IN FEMALES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-06-19 | — | — | US | disclosed |
| US-20250195496-A1 | AVPR1A BLOCKADE TO REDUCE SOCIAL ISOLATION-INDUCED ANXIETY IN FEMALES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-06-19 | — | — | US | disclosed |
| CN-118108723-A | Triazolobenzodiazepine compound and preparation method and application thereof | 暨南大学附属第一医院（广州华侨医院） | 2024-05-31 | — | — | CN | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2023164710-A1 | AVPR1A BLOCKADE TO REDUCE SOCIAL ISOLATION-INDUCED ANXIETY IN FEMALES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164710-A1 | AVPR1A BLOCKADE TO REDUCE SOCIAL ISOLATION-INDUCED ANXIETY IN FEMALES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | WO | disclosed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| CN-115350186-A | Application of SXR246 in preparation of medicine for treating traumatic brain injury and poor prognosis | 中国人民解放军军事科学院军事医学研究院 | 2022-11-18 | — | — | CN | disclosed |
| EP-3122743-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| US-20220098585-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | AVPR1A 2948/4885AVPR1B 1875/4885 |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | AVPR1A 2/4885AVPR1B 1/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | AVPR1A 4/4885AVPR1B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.